IBI363
Sponsors
Innovent Biologics (Suzhou) Co. Ltd., Hunan Province Tumor Hospital, Xiangdong Cheng, Shanghai Pulmonary Hospital, Shanghai, China, Fortvita Biologics (USA)Inc.
Conditions
Advan'ce'dAdvancedAdvanced Solid TumorAdvanced Solid TumorsColorectal CancerIBI363 + ChemotherapyMelanomaMetastatic Solid Tumors
Phase 1
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Active, not recruitingNCT05290597
Start: 2022-08-22End: 2026-12-31Updated: 2026-03-05
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
NCT05460767
Start: 2022-08-31End: 2024-12-31Target: 260Updated: 2023-12-29
The Efficacy and Safety of IBI363 in Solid Tumors
RecruitingNCT06081907
Start: 2023-12-25End: 2028-09-01Target: 430Updated: 2024-05-30
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
RecruitingNCT06610799
Start: 2024-10-15End: 2026-12-31Target: 40Updated: 2024-11-20
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruitingNCT07307053
Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
Not yet recruitingNCT07361991
Start: 2026-03-01End: 2030-09-01Target: 50Updated: 2026-01-23
Phase 2
A Study of IBI363 in Subjects With Advanced Melanoma
RecruitingNCT06081920
Start: 2023-10-19End: 2026-07-31Target: 150Updated: 2025-05-16
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RecruitingNCT06281678
Start: 2024-04-08End: 2026-12-31Target: 178Updated: 2024-12-19
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Not yet recruitingNCT06620822
Start: 2024-09-30End: 2027-09-30Target: 296Updated: 2024-10-01
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
RecruitingNCT06797297
Start: 2025-02-24End: 2027-06-30Target: 180Updated: 2025-04-04
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
RecruitingNCT07122687
Start: 2025-08-26End: 2030-04-30Target: 170Updated: 2025-09-30
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
Not yet recruitingNCT07402070
Start: 2026-02-04End: 2030-12-31Target: 10Updated: 2026-02-11